Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
643
mentions
- News 365
- X 150
- Blogs 44
- Facebook 42
- +2 more
